

Date: 13th November, 2021

To,
National Stock Exchange of India Limited
Exchange Plaza,
Plot no. C/1, G Block,
Bandra-Kurla Complex,
Bandra (E)
Mumbai – 400 051

Dear Sir / Ma'am,

Sub: Submission of Unaudited Financial Results for the Half Year ended on 30th September, 2021 along with Limited Review Report

Ref: Security Id: WALPAR/ Code: SM

In reference to captioned subject and pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Standalone and Consolidated Unaudited Financial Results for the Half Year ended on 30th September, 2021 along with Limited Review Report. .

Kindly take the same on your record and oblige us.

Thanking You,

For, **Walpar Nutritions Limited**

KALPESH
LADHAWALA

Digitally signed by
KALPESH LADHAWALA
Date: 2021.11.13
13:09:18 +05'30'

Kalpesh Ladhawala
Managing Director
DIN: 02849232

WALPAR NUTRITIONS LIMITED

(Formerly Known as WALPAR HEALTHCARE)

CIN - L24230GJ2020PLC118662

Registered Office: 2nd Floor L5:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India

Website - www.walparnutrition.com; Email : finance.walpar@hotmail.com

Standalone Statement of Unaudited Financial Results for the Half Year ended on September 30, 2021 Pursuant to regulation 33 of SEBI (LODR) Regulation, 2015 (Amount in Lakhs)

| | Particulars | Half Year ended on 30/09/2021 | Year to date figures for the half year ended on 30/09/2021 | Year to date figures for the year ended 31/03/2021 |
|-------|---|----------------------------------|--|--|
| | | Unaudited | Unaudited | Audited |
| | INCOME FROM OPERATIONS | | | |
| I | Revenue from Operations | 1397.90 | 1397.90 | 606.79 |
| II | Other Income | 4.30 | 4.30 | 0.44 |
| III | Total Revenue (I+II) | 1402.20 | 1402.20 | 607.23 |
| IV | EXPENSES | | | |
| | Cost of Material Consumed | 1123.36 | 1123.36 | 455.69 |
| | Purchase of Stock in Trade | 0.00 | 0.00 | 0.00 |
| | Change in inventories of Finished Goods, Work-in-progress & Stock in Trade | (14.35) | (14.35) | (28.40) |
| | Employee Benefit Expenses | 163.17 | 163.17 | 80.00 |
| | Finance Cost | 24.29 | 24.29 | 17.26 |
| | Depreciation & Amortization Expense | 13.39 | 13.39 | 11.89 |
| | Other Expenses | 71.94 | 71.94 | 54.40 |
| | Total expenses (IV) | 1381.81 | 1381.81 | 590.83 |
| V | Profit before Exceptional & Extraordinary Items and tax (III-IV) | 20.39 | 20.39 | 16.40 |
| VI | Exceptional Items | - | - | - |
| VII | Profit before Extraordinary Items and tax (V-VI) | 20.39 | 20.39 | 16.40 |
| VIII | Extraordinary Items | - | - | - |
| IX | Profit before tax (VII-VIII) | 20.39 | 20.39 | 16.40 |
| X | Tax Expenses | | | |
| | 1 Current Tax | 6.02 | 6.02 | 5.06 |
| | 2 Deferred Tax | (0.88) | (0.88) | (3.74) |
| | Total Tax Expenses (X) | 5.14 | 5.14 | 1.33 |
| XI | Profit/(Loss) for the period from continuing operations (IX-X) | 15.25 | 15.25 | 15.07 |
| XII | Profit/(Loss) from discontinuing operation | - | - | - |
| XIII | Tax Expenses of discontinuing operations | - | - | - |
| XIV | Profit/(Loss) from discontinuing operation after tax (XII-XIII) | - | - | - |
| XV | Profit/(Loss) for the Period (XI+XIV) | 15.25 | 15.25 | 15.07 |
| XVI | Paid up Equity Share Capital | 454.12 | 454.12 | 334.12 |
| XVII | Reserves & Surplus | 691.10 | 691.10 | 143.63 |
| XVIII | Earnings per equity share | | | |
| | (1) Basic | 0.39 | 0.39 | 0.47 |
| | (2) Diluted | 0.39 | 0.39 | 0.47 |

Notes:-

- The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on November 13, 2021
- The above result have been prepared in accordance with the Companies (Accounting standards) Rules, 2006 and Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014.
- The Statutory Auditors of the Company have carried out the Limited Review of the above financial results of the Company and have expressed an unmodified opinion on these Results.
- There are no investor complaints received/pending as on September 30, 2021
- Figures for the Preceding half Year Ended, Corresponding Half year Ended & Year to Date figures for the previous year ended are not available, since our company was not listed at that reporting period.
- AS 17 Relating to Segment wise reporting is not applicable as the Company operates in only One Primary segment i.e Manufacturing and Trading of Pharmaceutical, Nutraceutical, Herbal and Ayurvedic Commodities

| Sr. NO. | Particulars | Planned as per Prospectus | Utilization upto September 30, 2021 | Balance to be utilised as at September 30, 2021 |
|---------|---|---------------------------|--|---|
| 1 | Investment in Subsidiary | 180.00 | 180.00 | 0.00 |
| 2 | Incremental working Capital Requirement | 290.00 | 290.00 | 0.00 |
| 3 | General Corporate Purpose | 150.00 | 0.00 | 150.00 |
| 4 | Public Issue Expenses | 40.00 | 39.00 | 1.00 |
| | Total | 660.00 | 509.00 | 151.00 |

For Walpar Nutritions Limited

KALPESH
LADHAWALA

Digitally signed by
KALPESH LADHAWALA
Date: 2021.11.13
13:10:20 +05'30'

Kalpesh P Ladhawala
Managing Director
DIN : 02849232

Place : Gandhinagar

Date : November 13, 2021

WALPAR NUTRITIONS LIMITED
(Formerly Known as WALPAR HEALTHCARE)
CIN - L24230GJ2020PLC118662

Registered Office: 2nd Floor L5:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India

Website - www.walparnutritions.com; Email : finance.walpar@hotmail.com

Standalone Statement of Assets & Liabilities as on September 30, 2021

(Amount in Lakhs)

| Particulars | | As on 30th September 2021 | As on 31st March 2021 |
|-------------|---|------------------------------|--------------------------|
| | | Unaudited | Audited |
| I. | EQUITY AND LIABILITIES | | |
| 1 | Shareholders' funds | | |
| | Share capital | 454.12 | 334.12 |
| | Reserves and surplus | 691.10 | 143.63 |
| | | 1,145.22 | 477.76 |
| 2 | Non-current liabilities | | |
| | Long Term Borrowings | 432.55 | 262.53 |
| | Deferred Tax Liabilities (Net) | - | - |
| | Other Long Term Liabilities | - | - |
| | Long Term Provision | - | - |
| | | 432.55 | 262.53 |
| 3 | Current liabilities | | |
| | Short Term Borrowings | 248.49 | 188.55 |
| | Trade Payables | | |
| | (i) Total outstanding dues of micro enterprises and small enterprises | | - |
| | (ii) Total outstanding dues of creditors other than micro enterprises and small enterprises | 629.41 | 509.08 |
| | Other Current Liabilities | 36.36 | 142.71 |
| | Short Term Provisions | 6.02 | 5.06 |
| | | 920.29 | 845.41 |
| | TOTAL | 2,498.06 | 1,585.70 |
| II. | ASSETS | | |
| | Non-current assets | | |
| | Property Plant & Equipments | | |
| 1 | Fixed assets | | |
| | (i) Tangible Assets | 90.01 | 106.53 |
| | (ii) Intangible Assets | 10.12 | - |
| | Non Current Investments | 244.80 | 6.00 |
| | Long Term Loans & Advances | 57.10 | 54.00 |
| | Deferred Tax Assets | 4.61 | 3.73 |
| | Other Non Current Assets | 70.12 | 20.18 |
| | | 476.76 | 190.44 |
| 2 | Current assets | | |
| | Current Investments | | - |
| | Inventories | 554.15 | 433.07 |
| | Trade Receivables | 1,126.40 | 754.80 |
| | Cash and cash equivalents | 252.52 | 97.35 |
| | Short Term Loans & Advances | 60.19 | 100.41 |
| | Other Current Assets | 28.04 | 9.63 |
| | | 2,021.30 | 1,395.25 |
| | TOTAL | 2,498.06 | 1,585.70 |

For Walpar Nutritions Limited

KALPESH
LADHAWALA

Digitally signed by
KALPESH LADHAWALA
Date: 2021.11.13
13:10:45 +05'30'

Kalpesh P Ladhawala
Managing Director
DIN : 02849232

Place : Gandhinagar
Date : November 13, 2021

WALPAR NUTRITIONS LIMITED

(Formerly Known as WALPAR HEALTHCARE)

CIN - L24230GJ2020PLC118662

Registered Office: 2nd Floor L5:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India

Website - www.walparnutritions.com; Email : finance.walpar@hotmail.com

Standalone Statement of Cash Flows for the year ended on September 30, 2021

(Amount in Lakhs)

| Particulars | Half Year Ended on |
|---|--------------------|
| | 30.09.2021 |
| Cash flows from operating activities | |
| Profit before taxation | 20.39 |
| Adjustments for: | |
| Depreciation | 13.39 |
| Investment income | - |
| Finance Cost | 24.29 |
| Working capital changes: | |
| (Increase) / Decrease in Trade Receivables | (371.60) |
| (Increase) / Decrease in Short Term Loans & Advances | 40.22 |
| (Increase) / Decrease in Other Current Assets | (18.41) |
| (Increase) / Decrease in Inventories | (121.09) |
| Increase / (Decrease) in Trade Payables | 120.33 |
| Increase / (Decrease) in Other Current Liabilities | (106.35) |
| Cash generated from operations | (398.82) |
| Payment/Adjustmen on Account of Tax Expenses | (5.06) |
| Net cash from operating activities | (403.88) |
| Cash flows from investing activities | |
| Purchase of property, plant and equipment | (6.99) |
| Payment for Long Term Loans & Advances | (3.10) |
| (Increase)/Decrease in Other Non Current Assets | (49.94) |
| Increase in Non Current Investments | (238.80) |
| Net cash used in investing activities | (298.82) |
| Cash flows from financing activities | |
| Proceeds/ (Repayment) of Short term Borrowings | 59.94 |
| Proceeds/ (Repayment) of Long term Borrowings | 170.02 |
| Proceeds from Share Capital | 120.00 |
| Proceeds from Securities Premium | 532.21 |
| Payment of Finance cost | (24.29) |
| Net cash used in financing activities | 857.87 |
| Net increase in cash and cash equivalents | 155.17 |
| Cash and cash equivalents at beginning of period | 97.35 |
| Cash and cash equivalents at end of period | 252.52 |

For Walpar Nutritions Limited

KALPESH
LADHAWALA

Digitally signed by
KALPESH LADHAWALA
Date: 2021.11.13
13:11:03 +05'30'

Kalpesh P Ladhawala
Managing Director
DIN : 02849232

Place : Gandhinagar
Date : November 13, 2021



A Y & COMPANY

404, Fourth Floor, ARG Corporate Park
Gopal Bari, Ajmer Road, Jaipur (Raj.)
TEL NO. - +91-9649687300
Email: info@aycompany.co.in

Limited Review Report on the Half year ended Un-audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, As Amended

Review Report

To

**The Board of Directors
Walpar Nutritions Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Walpar Nutritions Limited** (the 'Company') for the Half Year ended on September 30, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 and Circular No. CIR/CFD/CMD1/80/2019 dated July 19, 2019 ('the Circular').
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Accounting Standard 25, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For A Y & Company
Chartered Accountants
FRN: 020829C**


**Arpit Gupta
Partner**

M. No. 421544

UDIN – 21421544AAAADF4804

Place: Gandhinagar

Date: 13.11.2021



WALPAR NUTRITIONS LIMITED

(Formerly Known as WALPAR HEALTHCARE)

CIN - L24230GJ2020PLC118662

Registered Office: 2nd Floor L5:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India

Website - www.walparnutritions.com; Email : finance.walpar@hotmail.com

Consolidated Statement of Unaudited Financial Results for the Half Year ended on September 30, 2021 Pursuant to regulation 33 of SEBI (LODR) Regulation, 2015

(Amount in Lakhs)

| | Particulars | Half Year ended on 30/09/2021 | Year to date figures for the half year ended on 30/09/2021 | Year to date figures for the year ended 31/03/2021 |
|--------------|---|----------------------------------|--|--|
| | | Unaudited | Unaudited | Audited |
| | INCOME FROM OPERATIONS | | | |
| I | Revenue from Operations | 1397.90 | 1397.90 | 606.79 |
| II | Other Income | 4.30 | 4.30 | 0.44 |
| III | Total Revenue (I+II) | 1402.20 | 1402.20 | 607.23 |
| IV | EXPENSES | | | |
| | Cost of Material Consumed | 1123.36 | 1123.36 | 455.69 |
| | Purchase of Stock in Trade | 0.00 | 0.00 | 0.00 |
| | Change in inventories of Finished Goods, Work-in-progress & Stock in Trade | (14.35) | (14.35) | (28.40) |
| | Employee Benefit Expenses | 163.17 | 163.17 | 80.00 |
| | Finance Cost | 24.59 | 24.59 | 17.26 |
| | Depreciation & Amortization Expense | 13.39 | 13.39 | 11.89 |
| | Other Expenses | 75.27 | 75.27 | 54.47 |
| | Total expenses (IV) | 1385.43 | 1385.43 | 590.90 |
| V | Profit before Exceptional & Extraordinary Items and tax (III-IV) | 16.77 | 16.77 | 16.33 |
| VI | Exceptional Items | - | - | - |
| VII | Profit before Extraordinary Items and tax (V-VI) | 16.77 | 16.77 | 16.33 |
| VIII | Extraordinary Items | - | - | - |
| IX | Profit before tax (VII-VIII) | 16.77 | 16.77 | 16.33 |
| X | Tax Expenses | | | |
| | 1 Current Tax | 5.80 | 5.80 | 5.06 |
| | 2 Deferred Tax | (0.88) | (0.88) | (3.74) |
| | Total Tax Expenses (X) | 4.92 | 4.92 | 1.33 |
| XI | Profit/(Loss) for the period from continuing operations (IX-X) | 11.85 | 11.85 | 15.00 |
| XII | Profit/(Loss) from discontinuing operation | - | - | - |
| XIII | Tax Expenses of discontinuing operations | - | - | - |
| XIV | Profit/(Loss) from discontinuing operation after tax (XII-XIII) | - | - | - |
| XV | Profit(Loss) for the Period (XI+XIV) | 11.85 | 11.85 | 15.00 |
| XVI | Profit Attributable to Minority Interest | -1.45 | -1.45 | -0.02 |
| XVII | Profit Attributable to Owners of Parent | 13.30 | 13.30 | 15.02 |
| XVIII | Paid up Equity Share Capital | 454.12 | 454.12 | 334.12 |
| XIX | Reserves & Surplus | 689.10 | 689.10 | 143.59 |
| XX | Earnings per equity share | | | |
| | (1) Basic | 0.30 | 0.30 | 0.46 |
| | (2) Diluted | 0.30 | 0.30 | 0.46 |

Notes:-

- The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on November 13, 2021
- The above result have been prepared in accordance with the Companies (Accounting standards) Rules, 2006 and Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014.
- The Statutory Auditors of the Company have carried out the Limited Review of the above financial results of the Company and have expressed an unmodified opinion on
- There are no investor complaints received/pending as on September 30, 2021
- Figures for the Preceding half Year Ended, Corresponding Half year Ended & Year to Date figures for the previous year ended are not available, since our company was not listed at that reporting period.
- AS 17 Relating to Segment wise reporting is not applicable as the Company operates in only One Primary segment i.e Manufacturing and Trading of Pharmaceutical, Nutraceutical, Herbal and Ayurvedic Commodities

For Walpar Nutritions Limited

KALPESH
LADHAWALA

Digitally signed by
KALPESH LADHAWALA
Date: 2021.11.13
13:11:23 +05'30'

Kalpesh P Ladhawala
Managing Director
DIN : 02849232

Place : Gandhinagar
Date : November 13, 2021

WALPAR NUTRITIONS LIMITED
(Formerly Known as WALPAR HEALTHCARE)
CIN - L24230GJ2020PLC118662

Registered Office: 2nd Floor L5:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India

Website - www.walparnutritions.com; Email : finance.walpar@hotmail.com

Consolidated Statement of Assets & Liabilities as on September 30, 2021

(Amount in Lakhs)

| Particulars | | As on 30th September 2021 | As on 31st March 2021 |
|-------------|---|------------------------------|--------------------------|
| | | Unaudited | Audited |
| I. | EQUITY AND LIABILITIES | | |
| 1 | Shareholders' funds | | |
| | Share capital | 454.12 | 334.12 |
| | Reserves and surplus | 689.10 | 143.58 |
| | | 1,143.22 | 477.70 |
| 2 | Minority Interest | 161.73 | 2.98 |
| 3 | Non-current liabilities | | |
| | Long Term Borrowings | 432.55 | 465.54 |
| | Deferred Tax Liabilities (Net) | - | - |
| | Other Long Term Liabilities | - | - |
| | Long Term Provision | - | - |
| | | 432.55 | 465.54 |
| 4 | Current liabilities | | |
| | Short Term Borrowings | 248.49 | 188.55 |
| | Trade Payables | | |
| | (i) Total outstanding dues of micro enterprises and small enterprises | | - |
| | (ii) Total outstanding dues of creditors other than micro enterprises and small enterprises | 629.41 | 534.17 |
| | Other Current Liabilities | 36.47 | 142.76 |
| | Short Term Provisions | 5.80 | 5.06 |
| | | 920.17 | 870.54 |
| | TOTAL | 2,657.68 | 1,816.76 |
| II. | ASSETS | | |
| | Non-current assets | | |
| | Property Plant & Equipments | | |
| 1 | Fixed assets | | |
| | (i) Tangible Assets | 196.59 | 170.49 |
| | (ii) Capital Work in Progress | 195.85 | 121.76 |
| | (iii) Intangible Assets | 10.12 | - |
| | Non Current Investments | - | - |
| | Long Term Loans & Advances | 37.50 | - |
| | Deferred Tax Assets | 4.61 | 3.73 |
| | Other Non Current Assets | 70.12 | 20.18 |
| | | 514.78 | 316.15 |
| 2 | Current assets | | |
| | Current Investments | | - |
| | Inventories | 554.15 | 433.07 |
| | Trade Receivables | 1,126.40 | 754.80 |
| | Cash and cash equivalents | 255.22 | 97.64 |
| | Short Term Loans & Advances | 146.74 | 187.17 |
| | Other Current Assets | 60.38 | 27.94 |
| | | 2,142.89 | 1,500.61 |
| | TOTAL | 2,657.68 | 1,816.76 |

For Walpar Nutritions Limited

KALPESH
LADHAWALA

Digitally signed by
KALPESH LADHAWALA
Date: 2021.11.13
13:11:43 +05'30'

Kalpesh P Ladhawala
Managing Director
DIN : 02849232

Place : Gandhinagar
Date : November 13, 2021

WALPAR NUTRITIONS LIMITED

(Formerly Known as WALPAR HEALTHCARE)

CIN - L24230GJ2020PLC118662

Registered Office: 2nd Floor L5:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India

Website - www.walparnutritions.com; Email : finance.walpar@hotmail.com

Consolidated Statement of Cash Flows for the year ended on September 30, 2021

(Amount in Lakhs)

| Particulars | Half Year Ended on |
|---|--------------------|
| | 30.09.2021 |
| Cash flows from operating activities | |
| Profit before taxation | 16.77 |
| Adjustments for: | |
| Depreciation | 13.39 |
| Investment income | - |
| Finance Cost | 24.59 |
| Working capital changes: | |
| (Increase) / Decrease in Trade Receivables | (371.60) |
| (Increase) / Decrease in Short Term Loans & Advances | 40.43 |
| (Increase) / Decrease in Other Current Assets | (32.44) |
| (Increase) / Decrease in Inventories | (121.09) |
| Increase / (Decrease) in Trade Payables | 95.24 |
| Increase / (Decrease) in Other Current Liabilities | (106.29) |
| Cash generated from operations | (441.00) |
| Payment/Adjustmen on Account of Tax Expenses | (5.06) |
| Net cash from operating activities | (446.06) |
| Cash flows from investing activities | |
| Purchase of property, plant and equipment | (123.70) |
| Payment for Long Term Loans & Advances | (37.50) |
| (Increase)/Decrease in Other Non Current Assets | (49.94) |
| Net cash used in investing activities | (211.13) |
| Cash flows from financing activities | |
| Proceeds/ (Repayment) of Short term Borrowings | 59.94 |
| Proceeds/ (Repayment) of Long term Borrowings | -32.99 |
| Proceeds from Share Capital | 120.00 |
| Proceeds from Securities Premium | 532.21 |
| Payment of Finance cost | (24.59) |
| Increase in Minority Interest | 160.20 |
| Net cash used in financing activities | 814.77 |
| Net increase in cash and cash equivalents | 157.58 |
| Cash and cash equivalents at beginning of period | 97.64 |
| Cash and cash equivalents at end of period | 255.22 |

For Walpar Nutritions Limited

KALPESH
LADHAWALA

Digitally signed by
KALPESH LADHAWALA
Date: 2021.11.13
13:11:58 +05'30'

Kalpesh P Ladhawala
Managing Director
DIN : 02849232

Place : Gandhinagar
Date : November 13, 2021



A Y & COMPANY

404, Fourth Floor, ARG Corporate Park
Gopal Bari, Ajmer Road, Jaipur (Raj.)
TEL NO. - +91-8003056441
Email: info@aycompany.co.in

Limited Review Report on the Half Year Ended Un-audited Consolidated Financial Results of company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report

To

**The Board of Directors
Walpar Nutritions Limited**

1. We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of Walpar Nutritions Limited ("the Parent"), which includes its subsidiary (the Parent and its subsidiary together referred to as 'the Group') for half year ended on September 30, 2021 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No. CIRICFD/CMD1/44/2019 dated March 29, 2019 and SEBI Circular No. CIR/CFD/CMD1/80/2019 dated July 19, 2019 ('the Circular').
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.



A Y & COMPANY

404, Fourth Floor, ARG Corporate Park
Gopal Bari, Ajmer Road, Jaipur (Raj.)
TEL NO. - +91-8003056441
Email: info@aycompany.co.in

4. The Statement includes the results of its subsidiaries:

1. Walpar Wellness Private Limited (A Company incorporated under Companies Act, 2013).

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the auditor's review reports of subsidiary companies referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes the unaudited interim financial results and other financial information of subsidiary company whose interim financial results reflects total assets as of Rs. 337.17 Lakhs, Total revenues for the half year ended on September 30, 2021, are Rs. NIL, total net profit (loss) after tax for the half year ended on September 30, 2021 is Rs. (3.62) Lakhs as considered in unaudited financial results.

For A Y & Company
Chartered Accountants
FRN: 020829C



Arpit Gupta
Partner
M. No. 421544
UDIN – 21421544AAAADG5556
Place: Gandhinagar
Date: 13.11.2021